Research published in the journal Clinical Science suggests that an immune signalling protein called interleukin -26 is increased among chronic smokers with lung disease and this involvement reveals disease mechanisms of interest for developing more effective therapy for these hard-to-treat patients. Chronic tobacco smokers have a substantially increased rate of chronic obstructive pulmonary disease , chronic bronchitis and bacterial lung infections and these disorders respond poorly to currently available therapies.


More...